MRSA and VRE

On this page

MRSA - The Staph Superbug

  • Mechanism: The mecA gene encodes Penicillin-Binding Protein 2a (PBP2a). This altered protein has a low affinity for β-lactam antibiotics, conferring resistance by preventing their binding.

  • Clinical Syndromes:

    • Community-Associated (CA-MRSA): Presents as skin/soft tissue infections (abscesses, boils). Virulence is often driven by Panton-Valentine Leukocidin (PVL) toxin.
    • Hospital-Associated (HA-MRSA): Causes more invasive disease (bacteremia, pneumonia, endocarditis) in patients with recent healthcare exposure.
  • Diagnosis:

    • Rapid: NAAT for the mecA gene offers fast identification.
    • Culture: Chromogenic agar for screening; Kirby-Bauer testing with a cefoxitin disk confirms resistance.

⭐ The PVL toxin in CA-MRSA is linked to severe, necrotizing pneumonia, classically seen in healthy patients following an influenza infection.

VRE - Vexing Vancomycin Villain

Vancomycin Resistance: VanA-type D-Ala-D-Lac Synthesis

  • Mechanism: Acquired vanA or vanB genes alter the peptidoglycan precursor target.
    • Terminal $D-Ala-D-Ala$ is changed to $D-Ala-D-Lac$.
    • This substitution prevents vancomycin from binding effectively.
  • Predominant Species:
    • Enterococcus faecium is more frequently vancomycin-resistant than E. faecalis.
  • Key Risk Factors:
    • Prolonged hospitalization or ICU stay.
    • Long-term antibiotic therapy, especially with vancomycin.
  • Clinical Syndromes:
    • Nosocomial infections, including UTIs, bacteremia, and endocarditis.

⭐ VRE can transfer its resistance genes to other bacteria, such as S. aureus, leading to the emergence of Vancomycin-Resistant Staphylococcus aureus (VRSA).

Treatment - The Resistance Rumble

DrugMechanism & Key Side EffectMRSAVRE
VancomycinInhibits cell wall synthesis by binding D-Ala-D-Ala. → Red Man Syndrome, nephrotoxicity.
DaptomycinLipopeptide; depolarizes cell membrane. → Myopathy (monitor CPK).
LinezolidBinds 50S subunit. → Thrombocytopenia, Serotonin Syndrome (risk with SSRIs).
Ceftaroline5th-gen cephalosporin; binds PBP2a. → Hemolytic anemia.
TigecyclineBinds 30S subunit. → Severe nausea/vomiting; ↑ mortality warning.
  • MRSA resistance stems from the mecA gene, encoding an altered penicillin-binding protein (PBP2a), making it impervious to most beta-lactams.
  • VRE resistance arises from the conversion of the peptidoglycan precursor from D-Ala-D-Ala to D-Ala-D-Lac.
  • Key MRSA treatments include Vancomycin, Linezolid, and Daptomycin.
  • For VRE, preferred agents are Linezolid and Daptomycin.
  • Both are significant causes of nosocomial infections, particularly in immunocompromised patients.

Practice Questions: MRSA and VRE

Test your understanding with these related questions

A 33-year-old man presents to the emergency department complaining of weakness and fatigue. He states that his symptoms have worsened over the past day. He has a past medical history of IV drug abuse and alcoholism and he currently smells of alcohol. His temperature is 102°F (38.9°C), blood pressure is 111/68 mmHg, pulse is 110/min, respirations are 17/min, and oxygen saturation is 98% on room air. Physical exam is notable for focal tenderness over the lumbar spine. Initial lab values and blood cultures are drawn and are notable for leukocytosis and an elevated C-reactive protein (CRP). Which of the following is the best treatment for this patient?

1 of 5

Flashcards: MRSA and VRE

1/10

_____ is a -lactamase producing bacteria resistant to penicillin.

TAP TO REVEAL ANSWER

_____ is a -lactamase producing bacteria resistant to penicillin.

Staph aureus

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial